PROCHLORPERAZINE (*Stemetil*) (C)

(Revised: November 2015)

TYPE:	Phenothiazine antiemetic [S4]
PRESENTATIONS:	12.5mg in 1ml – ampoule
ACTIONS:	Acts on several neurotransmitter systems: 1. antidopamine action 2. alpha-adrenergic antagonism 3. potentiates noradrenaline 4. weak anticholinergic and antihistamine effects 5. weak serotonin antagonism Onset IM: limited data. Duration IM: limited data – likely to be prolonged.

USE:	**ICP**	For the treatment (only) of nausea and vomiting from a variety of vestibular causes, including: motion sickness, migraine, vertigo and labyrinthitis	**AP**

ADVERSE EFFECTS:	1. *Gastrointestinal*: constipation, dry mouth 2. *Nervous system*: drowsiness, extrapyramidal symptoms 3. *Cardiovascular*: hypotension, ECG changes (especially QT prolongation) 4. *Respiratory*: respiratory depression
CONTRA-INDICATIONS:	1. Known hypersensitivity to phenothiazines 2. CNS depression 3. Shock from any cause, or other circulatory compromise 4. Not for use in pregnancy 5. Paediatric patients (<18 years old) 6. Not to be given in conjunction with intravenous amiodarone 7. Previous oral prochlorperazine within last 8 hours

continues over

PROCHLORPERAZINE (*Stemetil*) (C) – cont.

PRECAUTIONS:	1. Renal dysfunction 2. Parkinson's disease 3. Myasthenia gravis 4. Epilepsy 5. Caution in elderly – increased risk of dystonic reactions

DOSES:

ADULT:		
ICP	12.5mg deep IMI. *Single dose only.*	**AP**
PAEDIATRIC (<18 years old):		
	Not used.	

SPECIAL NOTE:

Patients who are administered prochlorperazine are not to be left at home, due to extensive adverse effect profile, potential symptom masking and extended half-life of the drug.